[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fHyMFf0iN3cx71m6Zoqix5FXk6PYFB0lreOwp7yqyRks":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":33,"phaseBuckets":84,"rows":91},"Seattle Children's Hospital",[4],208,false,55,8,57700,36,152,[14,17,20,22,24,26,28,31],{"name":15,"count":16},"Physical Activity",11,{"name":18,"count":19},"Cystic Fibrosis",6,{"name":21,"count":19},"Concussion, Brain",{"name":23,"count":19},"Depression",{"name":25,"count":19},"Germ Cell Tumor",{"name":27,"count":19},"Chronic Pain",{"name":29,"count":30},"Asthma",5,{"name":32,"count":30},"Childhood Obesity",[34,39,44,49,54,59,64,69,74,79],{"nctId":35,"briefTitle":36,"date":37,"intervention":38},"NCT01683279","A Pediatric Trial of Genetically Modified Autologous T Cells Directed Against CD19 for Relapsed CD19+ Acute Lymphoblastic Leukemia","2015-01-07","Autologous CD19 CAR+ EGFTt + T cells",{"nctId":40,"briefTitle":41,"date":42,"intervention":43},"NCT03244306","A Phase 1 Study of CD22-CAR TCell Immunotherapy for CD22+ Leukemia and Lymphoma","2018-11-14","Patient-derived CD22-specific CAR T-cells also expressing an EGFRt",{"nctId":45,"briefTitle":46,"date":47,"intervention":48},"NCT03684889","CD19-specific CAR T Cells With a Fully Human Binding Domain for CD19+ Leukemia or Lymphoma","2021-02-08","SCRI-huCAR19v1",{"nctId":50,"briefTitle":51,"date":52,"intervention":53},"NCT02028455","A Pediatric and Young Adult Trial of Genetically Modified T Cells Directed Against CD19 for Relapsed\u002FRefractory CD19+ Leukemia","2021-08-10","Patient Derived CD19 specific CAR T cells also expressing an EGFRt",{"nctId":55,"briefTitle":56,"date":57,"intervention":58},"NCT03186118","Pilot Study of T-APCs Following CAR T Cell Immunotherapy for CD19+ Leukemia","2021-09-13","T-cell Antigen Presenting Cells expressing truncated CD19",{"nctId":60,"briefTitle":61,"date":62,"intervention":63},"NCT02543866","Fecal Microbiota Transplantation as a Strategy to Eradicate Resistant Organisms","2023-09","Fecal Microbiota Transplantation",{"nctId":65,"briefTitle":66,"date":67,"intervention":68},"NCT03330691","A Feasibility and Safety Study of Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy for CD19+CD22+ Leukemia","2023-09-13","Patient-derived CD19- and CD22 specific CAR",{"nctId":70,"briefTitle":71,"date":72,"intervention":73},"NCT02311621","Engineered Neuroblastoma Cellular Immunotherapy (ENCIT)-01","2023-11","Patient Derived CD171 specific CAR T cells expressing EGFRt",{"nctId":75,"briefTitle":76,"date":77,"intervention":78},"NCT03500991","HER2-specific CAR T Cell Locoregional Immunotherapy for HER2-positive Recurrent\u002FRefractory Pediatric CNS Tumors","2024-01-17","HER2-specific chimeric antigen receptor (CAR) T cell",{"nctId":80,"briefTitle":81,"date":82,"intervention":83},"NCT05312411","A Phase I Feasibility And Safety Study of Fluorescein-Specific (FITC-E2) CAR T Cells In Combination With Parenterally Administered Folate-Fluorescein (UB-TT170) For Osteogenic Sarcoma","2025-03-12","SCRI-E2CAR_EGFRtv1",[85,86,87,88,89,90],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[92,120,142,171,198,244,267,289,325,343,364,386,404,425,446,464,485,520,548,572,598,626,653,671,689,711,763,781,799,817,835,853,871,889,907,925,943,980,998,1023,1041,1068,1095,1113,1131,1149,1187,1212,1230,1256,1274,1299,1325,1353,1371,1396,1414,1441,1468,1486,1504,1532,1550,1568,1586,1616,1639,1663,1692,1710,1728,1746,1764,1789,1812,1836,1862,1880,1898,1924,1948,1992,2025,2043,2061,2079,2097,2115,2133,2151,2178,2196,2214,2240,2272,2290,2308,2326,2344,2362,2380,2398,2416,2434,2452,2470,2488],{"intervention":93,"totalTrials":94,"cells":95},"Exenatide 2 mg [Bydureon]",1,{"EARLY_PHASE1":96,"PHASE1":99,"PHASE2":101,"PHASE3":103,"PHASE4":116,"NA":118},{"trials":97,"activeCount":98},[],0,{"trials":100,"activeCount":98},[],{"trials":102,"activeCount":98},[],{"trials":104,"activeCount":94,"soonestReadout":110},[105],{"nctId":106,"briefTitle":107,"status":108,"phases":109,"primaryCompletion":110,"completion":111,"start":112,"enrollment":113,"conditions":114,"interventions":115},"NCT04520490","Brain Activation and Satiety in Children 2","ACTIVE_NOT_RECRUITING",[88],"2025-08-21","2026-02-12","2021-01-28",63,[32],[93],{"trials":117,"activeCount":98},[],{"trials":119,"activeCount":98},[],{"intervention":53,"totalTrials":94,"cells":121},{"EARLY_PHASE1":122,"PHASE1":124,"PHASE2":126,"PHASE3":136,"PHASE4":138,"NA":140},{"trials":123,"activeCount":98},[],{"trials":125,"activeCount":98},[],{"trials":127,"activeCount":94,"soonestReadout":52},[128],{"nctId":50,"briefTitle":51,"status":108,"phases":129,"primaryCompletion":52,"completion":130,"start":131,"enrollment":132,"conditions":133,"interventions":135},[86,87],"2036-07","2014-02-11",167,[134],"CD19+ Acute Leukemia",[53],{"trials":137,"activeCount":98},[],{"trials":139,"activeCount":98},[],{"trials":141,"activeCount":98},[],{"intervention":143,"totalTrials":94,"cells":144},"Phentermine \u002F Topiramate Extended Release Oral Capsule [Qsymia]",{"EARLY_PHASE1":145,"PHASE1":147,"PHASE2":149,"PHASE3":165,"PHASE4":167,"NA":169},{"trials":146,"activeCount":98},[],{"trials":148,"activeCount":98},[],{"trials":150,"activeCount":94,"soonestReadout":156},[151],{"nctId":152,"briefTitle":153,"status":154,"phases":155,"primaryCompletion":156,"completion":157,"start":158,"enrollment":159,"conditions":160,"interventions":164},"NCT06299891","Efficacy and Safety of Phentermine\u002FTopiramate in Youth With Hypothalamic Obesity","RECRUITING",[87],"2026-02-28","2026-05-31","2025-03-01",24,[161,162,163],"Hypothalamic Obesity","Hypothalamic Tumor","Craniopharyngioma",[143],{"trials":166,"activeCount":98},[],{"trials":168,"activeCount":98},[],{"trials":170,"activeCount":98},[],{"intervention":172,"totalTrials":94,"cells":173},"SCRI-CAR22v2",{"EARLY_PHASE1":174,"PHASE1":176,"PHASE2":178,"PHASE3":192,"PHASE4":194,"NA":196},{"trials":175,"activeCount":98},[],{"trials":177,"activeCount":98},[],{"trials":179,"activeCount":94,"soonestReadout":184},[180],{"nctId":181,"briefTitle":182,"status":108,"phases":183,"primaryCompletion":184,"completion":185,"start":186,"enrollment":187,"conditions":188,"interventions":191},"NCT04571138","A Pediatric and Young Adult Trial of Genetically Modified T Cells Directed Against CD22 for Relapsed\u002FRefractory Leukemia or Lymphoma",[86,87],"2025-08-08","2040-02","2020-09-25",42,[189,190],"Leukemia","Lymphoma",[172],{"trials":193,"activeCount":98},[],{"trials":195,"activeCount":98},[],{"trials":197,"activeCount":98},[],{"intervention":199,"totalTrials":200,"cells":201},"SC-CAR.GPC3xIL15.21 CAR T cells",2,{"EARLY_PHASE1":202,"PHASE1":204,"PHASE2":236,"PHASE3":238,"PHASE4":240,"NA":242},{"trials":203,"activeCount":98},[],{"trials":205,"activeCount":200,"soonestReadout":210},[206,226],{"nctId":207,"briefTitle":208,"status":154,"phases":209,"primaryCompletion":210,"completion":211,"start":212,"enrollment":213,"conditions":214,"interventions":225},"NCT07148050","Immunotherapy for Solid Tumor Malignancies in Pediatrics Using Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor T Cells",[86],"2029-04-22","2044-04-22","2025-12-22",21,[215,216,217,218,219,220,221,222,223,224],"Solid Tumor (Excluding CNS)","Liver Cell Carcinoma","Malignant Rhabdoid Tumor","Yolk Sac Tumor","Liposarcoma","Rhabdomyosarcoma","Embryonal Sarcoma of Liver","Wilms Tumor","Hepatocellular Carcinoma","Hepatoblastoma",[199],{"nctId":227,"briefTitle":228,"status":229,"phases":230,"primaryCompletion":231,"completion":232,"start":233,"enrollment":213,"conditions":234,"interventions":235},"NCT07224568","Cytokine Armored GPC3 Specific Chimeric Antigen Receptor Expressing T-cells in Adults With Solid Tumors","NOT_YET_RECRUITING",[86],"2030-08","2045-08","2026-04-01",[215,223,216,219,218,220],[199],{"trials":237,"activeCount":98},[],{"trials":239,"activeCount":98},[],{"trials":241,"activeCount":98},[],{"trials":243,"activeCount":98},[],{"intervention":73,"totalTrials":94,"cells":245},{"EARLY_PHASE1":246,"PHASE1":248,"PHASE2":259,"PHASE3":261,"PHASE4":263,"NA":265},{"trials":247,"activeCount":98},[],{"trials":249,"activeCount":94,"soonestReadout":72},[250],{"nctId":70,"briefTitle":71,"status":108,"phases":251,"primaryCompletion":72,"completion":252,"start":253,"enrollment":254,"conditions":255,"interventions":258},[86],"2038-11","2014-11-25",65,[256,257],"Neuroblastoma","Ganglioneuroblastoma",[73,73,73],{"trials":260,"activeCount":98},[],{"trials":262,"activeCount":98},[],{"trials":264,"activeCount":98},[],{"trials":266,"activeCount":98},[],{"intervention":58,"totalTrials":94,"cells":268},{"EARLY_PHASE1":269,"PHASE1":271,"PHASE2":281,"PHASE3":283,"PHASE4":285,"NA":287},{"trials":270,"activeCount":98},[],{"trials":272,"activeCount":94,"soonestReadout":57},[273],{"nctId":55,"briefTitle":56,"status":108,"phases":274,"primaryCompletion":57,"completion":275,"start":276,"enrollment":277,"conditions":278,"interventions":280},[86],"2033-07","2017-08-04",30,[279],"CD 19+ Acute Leukemia",[58],{"trials":282,"activeCount":98},[],{"trials":284,"activeCount":98},[],{"trials":286,"activeCount":98},[],{"trials":288,"activeCount":98},[],{"intervention":290,"totalTrials":94,"cells":291},"second generation 4-1BBζ EGFR806-EGFRt",{"EARLY_PHASE1":292,"PHASE1":294,"PHASE2":317,"PHASE3":319,"PHASE4":321,"NA":323},{"trials":293,"activeCount":98},[],{"trials":295,"activeCount":94,"soonestReadout":300},[296],{"nctId":297,"briefTitle":298,"status":108,"phases":299,"primaryCompletion":300,"completion":300,"start":301,"enrollment":302,"conditions":303,"interventions":315},"NCT03618381","EGFR806 CAR T Cell Immunotherapy for Recurrent\u002FRefractory Solid Tumors in Children and Young Adults",[86],"2040-06","2019-06-18",44,[304,25,305,224,222,306,307,308,309,220,310,311,312,313,314,256],"Pediatric Solid Tumor","Retinoblastoma","Rhabdoid Tumor","Carcinoma","Osteosarcoma","Ewing Sarcoma","Synovial Sarcoma","Clear Cell Sarcoma","Malignant Peripheral Nerve Sheath Tumors","Desmoplastic Small Round Cell Tumor","Soft Tissue Sarcoma",[290,316],"second generation 4-1BBζ EGFR806-EGFRt and a second generation 4 1BBζ CD19-Her2tG",{"trials":318,"activeCount":98},[],{"trials":320,"activeCount":98},[],{"trials":322,"activeCount":98},[],{"trials":324,"activeCount":98},[],{"intervention":316,"totalTrials":94,"cells":326},{"EARLY_PHASE1":327,"PHASE1":329,"PHASE2":335,"PHASE3":337,"PHASE4":339,"NA":341},{"trials":328,"activeCount":98},[],{"trials":330,"activeCount":94,"soonestReadout":300},[331],{"nctId":297,"briefTitle":298,"status":108,"phases":332,"primaryCompletion":300,"completion":300,"start":301,"enrollment":302,"conditions":333,"interventions":334},[86],[304,25,305,224,222,306,307,308,309,220,310,311,312,313,314,256],[290,316],{"trials":336,"activeCount":98},[],{"trials":338,"activeCount":98},[],{"trials":340,"activeCount":98},[],{"trials":342,"activeCount":98},[],{"intervention":38,"totalTrials":94,"cells":344},{"EARLY_PHASE1":345,"PHASE1":347,"PHASE2":356,"PHASE3":358,"PHASE4":360,"NA":362},{"trials":346,"activeCount":98},[],{"trials":348,"activeCount":94,"soonestReadout":37},[349],{"nctId":35,"briefTitle":36,"status":108,"phases":350,"primaryCompletion":37,"completion":351,"start":352,"enrollment":19,"conditions":353,"interventions":355},[86],"2030-01-07","2012-03-25",[354],"B Cell Leukemia",[38],{"trials":357,"activeCount":98},[],{"trials":359,"activeCount":98},[],{"trials":361,"activeCount":98},[],{"trials":363,"activeCount":98},[],{"intervention":48,"totalTrials":94,"cells":365},{"EARLY_PHASE1":366,"PHASE1":368,"PHASE2":378,"PHASE3":380,"PHASE4":382,"NA":384},{"trials":367,"activeCount":98},[],{"trials":369,"activeCount":94,"soonestReadout":47},[370],{"nctId":45,"briefTitle":46,"status":108,"phases":371,"primaryCompletion":47,"completion":372,"start":373,"enrollment":374,"conditions":375,"interventions":376},[86],"2036-12","2018-11-28",16,[189,190],[48,377],"SCRI-huCAR19v2",{"trials":379,"activeCount":98},[],{"trials":381,"activeCount":98},[],{"trials":383,"activeCount":98},[],{"trials":385,"activeCount":98},[],{"intervention":377,"totalTrials":94,"cells":387},{"EARLY_PHASE1":388,"PHASE1":390,"PHASE2":396,"PHASE3":398,"PHASE4":400,"NA":402},{"trials":389,"activeCount":98},[],{"trials":391,"activeCount":94,"soonestReadout":47},[392],{"nctId":45,"briefTitle":46,"status":108,"phases":393,"primaryCompletion":47,"completion":372,"start":373,"enrollment":374,"conditions":394,"interventions":395},[86],[189,190],[48,377],{"trials":397,"activeCount":98},[],{"trials":399,"activeCount":98},[],{"trials":401,"activeCount":98},[],{"trials":403,"activeCount":98},[],{"intervention":68,"totalTrials":94,"cells":405},{"EARLY_PHASE1":406,"PHASE1":408,"PHASE2":417,"PHASE3":419,"PHASE4":421,"NA":423},{"trials":407,"activeCount":98},[],{"trials":409,"activeCount":94,"soonestReadout":67},[410],{"nctId":65,"briefTitle":66,"status":108,"phases":411,"primaryCompletion":67,"completion":412,"start":413,"enrollment":414,"conditions":415,"interventions":416},[86],"2035-03-03","2017-11-03",78,[189,190],[68],{"trials":418,"activeCount":98},[],{"trials":420,"activeCount":98},[],{"trials":422,"activeCount":98},[],{"trials":424,"activeCount":98},[],{"intervention":83,"totalTrials":94,"cells":426},{"EARLY_PHASE1":427,"PHASE1":429,"PHASE2":438,"PHASE3":440,"PHASE4":442,"NA":444},{"trials":428,"activeCount":98},[],{"trials":430,"activeCount":94,"soonestReadout":82},[431],{"nctId":80,"briefTitle":81,"status":108,"phases":432,"primaryCompletion":82,"completion":433,"start":434,"enrollment":213,"conditions":435,"interventions":436},[86],"2040-05","2022-05-20",[308],[83,437],"UB_TT170",{"trials":439,"activeCount":98},[],{"trials":441,"activeCount":98},[],{"trials":443,"activeCount":98},[],{"trials":445,"activeCount":98},[],{"intervention":437,"totalTrials":94,"cells":447},{"EARLY_PHASE1":448,"PHASE1":450,"PHASE2":456,"PHASE3":458,"PHASE4":460,"NA":462},{"trials":449,"activeCount":98},[],{"trials":451,"activeCount":94,"soonestReadout":82},[452],{"nctId":80,"briefTitle":81,"status":108,"phases":453,"primaryCompletion":82,"completion":433,"start":434,"enrollment":213,"conditions":454,"interventions":455},[86],[308],[83,437],{"trials":457,"activeCount":98},[],{"trials":459,"activeCount":98},[],{"trials":461,"activeCount":98},[],{"trials":463,"activeCount":98},[],{"intervention":43,"totalTrials":94,"cells":465},{"EARLY_PHASE1":466,"PHASE1":468,"PHASE2":477,"PHASE3":479,"PHASE4":481,"NA":483},{"trials":467,"activeCount":98},[],{"trials":469,"activeCount":94,"soonestReadout":42},[470],{"nctId":40,"briefTitle":41,"status":108,"phases":471,"primaryCompletion":42,"completion":472,"start":473,"enrollment":474,"conditions":475,"interventions":476},[86],"2035-07","2017-07-27",4,[189],[43],{"trials":478,"activeCount":98},[],{"trials":480,"activeCount":98},[],{"trials":482,"activeCount":98},[],{"trials":484,"activeCount":98},[],{"intervention":486,"totalTrials":94,"cells":487},"SCRI-CARB7H3(s); B7H3-specific chimeric antigen receptor (CAR) T cel",{"EARLY_PHASE1":488,"PHASE1":490,"PHASE2":512,"PHASE3":514,"PHASE4":516,"NA":518},{"trials":489,"activeCount":98},[],{"trials":491,"activeCount":94,"soonestReadout":496},[492],{"nctId":493,"briefTitle":494,"status":154,"phases":495,"primaryCompletion":496,"completion":497,"start":498,"enrollment":499,"conditions":500,"interventions":511},"NCT04185038","Study of B7-H3-Specific CAR T Cell Locoregional Immunotherapy for Diffuse Intrinsic Pontine Glioma\u002FDiffuse Midline Glioma and Recurrent or Refractory Pediatric Central Nervous System Tumors",[86],"2027-05","2042-05","2019-12-11",90,[501,502,503,504,505,25,506,507,508,509,510],"Central Nervous System Tumor","Diffuse Intrinsic Pontine Glioma","Diffuse Midline Glioma","Ependymoma","Medulloblastoma, Childhood","Atypical Teratoid\u002FRhabdoid Tumor","Primitive Neuroectodermal Tumor","Choroid Plexus Carcinoma","Pineoblastoma, Childhood","Glioma",[486],{"trials":513,"activeCount":98},[],{"trials":515,"activeCount":98},[],{"trials":517,"activeCount":98},[],{"trials":519,"activeCount":98},[],{"intervention":521,"totalTrials":94,"cells":522},"SC-DARIC33",{"EARLY_PHASE1":523,"PHASE1":525,"PHASE2":540,"PHASE3":542,"PHASE4":544,"NA":546},{"trials":524,"activeCount":98},[],{"trials":526,"activeCount":94,"soonestReadout":531},[527],{"nctId":528,"briefTitle":529,"status":154,"phases":530,"primaryCompletion":531,"completion":532,"start":533,"enrollment":534,"conditions":535,"interventions":539},"NCT05105152","PLAT-08: A Study Of SC-DARIC33 CAR T Cells In Pediatric And Young Adults With Relapsed Or Refractory CD33+ AML",[86],"2028-02-28","2041-01-31","2021-11-29",18,[536,537,538],"Acute Myeloid Leukemia","Acute Myeloid Leukemia Refractory","Acute Myeloid Leukemia, in Relapse",[521],{"trials":541,"activeCount":98},[],{"trials":543,"activeCount":98},[],{"trials":545,"activeCount":98},[],{"trials":547,"activeCount":98},[],{"intervention":78,"totalTrials":94,"cells":549},{"EARLY_PHASE1":550,"PHASE1":552,"PHASE2":564,"PHASE3":566,"PHASE4":568,"NA":570},{"trials":551,"activeCount":98},[],{"trials":553,"activeCount":94,"soonestReadout":77},[554],{"nctId":75,"briefTitle":76,"status":108,"phases":555,"primaryCompletion":77,"completion":556,"start":557,"enrollment":558,"conditions":559,"interventions":563},[86],"2039-07-26","2018-07-26",10,[560,510,504,561,25,506,507,508,562],"Central Nervous System Tumor, Pediatric","Medulloblastoma","Pineoblastoma",[78],{"trials":565,"activeCount":98},[],{"trials":567,"activeCount":98},[],{"trials":569,"activeCount":98},[],{"trials":571,"activeCount":98},[],{"intervention":573,"totalTrials":94,"cells":574},"SCRI-CAR19v3",{"EARLY_PHASE1":575,"PHASE1":577,"PHASE2":590,"PHASE3":592,"PHASE4":594,"NA":596},{"trials":576,"activeCount":98},[],{"trials":578,"activeCount":94,"soonestReadout":583},[579],{"nctId":580,"briefTitle":581,"status":154,"phases":582,"primaryCompletion":583,"completion":584,"start":585,"enrollment":586,"conditions":587,"interventions":589},"NCT06465147","REACT-01: Reversing Autoimmunity Through Cell Therapy",[86],"2028-10","2041-10","2024-12-16",12,[588],"Systemic Lupus Erythematosus",[573],{"trials":591,"activeCount":98},[],{"trials":593,"activeCount":98},[],{"trials":595,"activeCount":98},[],{"trials":597,"activeCount":98},[],{"intervention":599,"totalTrials":94,"cells":600},"SC-CAR4BRAIN",{"EARLY_PHASE1":601,"PHASE1":603,"PHASE2":618,"PHASE3":620,"PHASE4":622,"NA":624},{"trials":602,"activeCount":98},[],{"trials":604,"activeCount":94,"soonestReadout":609},[605],{"nctId":606,"briefTitle":607,"status":108,"phases":608,"primaryCompletion":609,"completion":610,"start":611,"enrollment":612,"conditions":613,"interventions":617},"NCT05768880","Study of B7-H3, EGFR806, HER2, And IL13-Zetakine (Quad) CAR T Cell Locoregional Immunotherapy For Pediatric Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, And Recurrent Or Refractory Central Nervous System Tumors",[86],"2028-01-15","2043-12-31","2023-05-05",72,[502,503,614,615,616],"Recurrent CNS Tumor, Adult","Recurrent, CNS Tumor, Childhood","Refractory Primary Malignant Central Nervous System Neoplasm",[599],{"trials":619,"activeCount":98},[],{"trials":621,"activeCount":98},[],{"trials":623,"activeCount":98},[],{"trials":625,"activeCount":98},[],{"intervention":627,"totalTrials":94,"cells":628},"second generation 4-1BBζ B7H3-EGFRt-DHFR",{"EARLY_PHASE1":629,"PHASE1":631,"PHASE2":645,"PHASE3":647,"PHASE4":649,"NA":651},{"trials":630,"activeCount":98},[],{"trials":632,"activeCount":94,"soonestReadout":637},[633],{"nctId":634,"briefTitle":635,"status":108,"phases":636,"primaryCompletion":637,"completion":637,"start":638,"enrollment":639,"conditions":640,"interventions":642},"NCT04483778","B7H3 CAR T Cell Immunotherapy for Recurrent\u002FRefractory Solid Tumors in Children and Young Adults",[86],"2040-12","2020-07-13",68,[304,25,305,224,222,306,307,308,309,220,310,311,312,313,314,256,641],"Melanoma",[627,643,644],"second generation 4-1BBζ B7H3-EGFRt-DHFR(selected) and a second generation 4-1BBζ CD19-Her2tG","Pembrolizumab",{"trials":646,"activeCount":98},[],{"trials":648,"activeCount":98},[],{"trials":650,"activeCount":98},[],{"trials":652,"activeCount":98},[],{"intervention":643,"totalTrials":94,"cells":654},{"EARLY_PHASE1":655,"PHASE1":657,"PHASE2":663,"PHASE3":665,"PHASE4":667,"NA":669},{"trials":656,"activeCount":98},[],{"trials":658,"activeCount":94,"soonestReadout":637},[659],{"nctId":634,"briefTitle":635,"status":108,"phases":660,"primaryCompletion":637,"completion":637,"start":638,"enrollment":639,"conditions":661,"interventions":662},[86],[304,25,305,224,222,306,307,308,309,220,310,311,312,313,314,256,641],[627,643,644],{"trials":664,"activeCount":98},[],{"trials":666,"activeCount":98},[],{"trials":668,"activeCount":98},[],{"trials":670,"activeCount":98},[],{"intervention":644,"totalTrials":94,"cells":672},{"EARLY_PHASE1":673,"PHASE1":675,"PHASE2":681,"PHASE3":683,"PHASE4":685,"NA":687},{"trials":674,"activeCount":98},[],{"trials":676,"activeCount":94,"soonestReadout":637},[677],{"nctId":634,"briefTitle":635,"status":108,"phases":678,"primaryCompletion":637,"completion":637,"start":638,"enrollment":639,"conditions":679,"interventions":680},[86],[304,25,305,224,222,306,307,308,309,220,310,311,312,313,314,256,641],[627,643,644],{"trials":682,"activeCount":98},[],{"trials":684,"activeCount":98},[],{"trials":686,"activeCount":98},[],{"trials":688,"activeCount":98},[],{"intervention":63,"totalTrials":94,"cells":690},{"EARLY_PHASE1":691,"PHASE1":693,"PHASE2":703,"PHASE3":705,"PHASE4":707,"NA":709},{"trials":692,"activeCount":98},[],{"trials":694,"activeCount":94,"soonestReadout":62},[695],{"nctId":60,"briefTitle":61,"status":154,"phases":696,"primaryCompletion":62,"completion":697,"start":698,"enrollment":699,"conditions":700,"interventions":702},[86],"2026-09","2017-02-17",20,[701],"Infection Resistant to Drugs",[63],{"trials":704,"activeCount":98},[],{"trials":706,"activeCount":98},[],{"trials":708,"activeCount":98},[],{"trials":710,"activeCount":98},[],{"intervention":712,"totalTrials":200,"cells":713},"methotrexate",{"EARLY_PHASE1":714,"PHASE1":716,"PHASE2":718,"PHASE3":720,"PHASE4":722,"NA":738},{"trials":715,"activeCount":98},[],{"trials":717,"activeCount":98},[],{"trials":719,"activeCount":98},[],{"trials":721,"activeCount":98},[],{"trials":723,"activeCount":98},[724],{"nctId":725,"briefTitle":726,"status":727,"phases":728,"primaryCompletion":729,"completion":729,"start":730,"enrollment":731,"conditions":732,"interventions":736},"NCT00443430","Trial of Early Aggressive Drug Therapy in Juvenile Idiopathic Arthritis","COMPLETED",[89],"2010-10","2007-05",85,[733,734,735],"Juvenile Chronic Polyarthritis","Juvenile Idiopathic Arthritis","Juvenile Rheumatoid Arthritis",[712,737],"methotrexate - etanercept - prednisolone arm",{"trials":739,"activeCount":94,"soonestReadout":744},[740],{"nctId":741,"briefTitle":742,"status":154,"phases":743,"primaryCompletion":744,"completion":745,"start":746,"enrollment":747,"conditions":748,"interventions":751},"NCT04725422","CHronic Nonbacterial Osteomyelitis International Registry",[],"2028-08","2050-08","2018-08-01",2000,[749,750],"Chronic Nonbacterial Osteomyelitis","Chronic Recurrent Multifocal Osteomyelitis",[752,753,754,755,756,757,758,759,760,761,762],"Methotrexate","Sulfasalazine","Leflunomide","Pamidronate","Zoledronic acid","Etanercept","Adalimumab","Certolizumab","Infliximab","Golimumab","NSAID",{"intervention":753,"totalTrials":94,"cells":764},{"EARLY_PHASE1":765,"PHASE1":767,"PHASE2":769,"PHASE3":771,"PHASE4":773,"NA":775},{"trials":766,"activeCount":98},[],{"trials":768,"activeCount":98},[],{"trials":770,"activeCount":98},[],{"trials":772,"activeCount":98},[],{"trials":774,"activeCount":98},[],{"trials":776,"activeCount":94,"soonestReadout":744},[777],{"nctId":741,"briefTitle":742,"status":154,"phases":778,"primaryCompletion":744,"completion":745,"start":746,"enrollment":747,"conditions":779,"interventions":780},[],[749,750],[752,753,754,755,756,757,758,759,760,761,762],{"intervention":754,"totalTrials":94,"cells":782},{"EARLY_PHASE1":783,"PHASE1":785,"PHASE2":787,"PHASE3":789,"PHASE4":791,"NA":793},{"trials":784,"activeCount":98},[],{"trials":786,"activeCount":98},[],{"trials":788,"activeCount":98},[],{"trials":790,"activeCount":98},[],{"trials":792,"activeCount":98},[],{"trials":794,"activeCount":94,"soonestReadout":744},[795],{"nctId":741,"briefTitle":742,"status":154,"phases":796,"primaryCompletion":744,"completion":745,"start":746,"enrollment":747,"conditions":797,"interventions":798},[],[749,750],[752,753,754,755,756,757,758,759,760,761,762],{"intervention":755,"totalTrials":94,"cells":800},{"EARLY_PHASE1":801,"PHASE1":803,"PHASE2":805,"PHASE3":807,"PHASE4":809,"NA":811},{"trials":802,"activeCount":98},[],{"trials":804,"activeCount":98},[],{"trials":806,"activeCount":98},[],{"trials":808,"activeCount":98},[],{"trials":810,"activeCount":98},[],{"trials":812,"activeCount":94,"soonestReadout":744},[813],{"nctId":741,"briefTitle":742,"status":154,"phases":814,"primaryCompletion":744,"completion":745,"start":746,"enrollment":747,"conditions":815,"interventions":816},[],[749,750],[752,753,754,755,756,757,758,759,760,761,762],{"intervention":756,"totalTrials":94,"cells":818},{"EARLY_PHASE1":819,"PHASE1":821,"PHASE2":823,"PHASE3":825,"PHASE4":827,"NA":829},{"trials":820,"activeCount":98},[],{"trials":822,"activeCount":98},[],{"trials":824,"activeCount":98},[],{"trials":826,"activeCount":98},[],{"trials":828,"activeCount":98},[],{"trials":830,"activeCount":94,"soonestReadout":744},[831],{"nctId":741,"briefTitle":742,"status":154,"phases":832,"primaryCompletion":744,"completion":745,"start":746,"enrollment":747,"conditions":833,"interventions":834},[],[749,750],[752,753,754,755,756,757,758,759,760,761,762],{"intervention":757,"totalTrials":94,"cells":836},{"EARLY_PHASE1":837,"PHASE1":839,"PHASE2":841,"PHASE3":843,"PHASE4":845,"NA":847},{"trials":838,"activeCount":98},[],{"trials":840,"activeCount":98},[],{"trials":842,"activeCount":98},[],{"trials":844,"activeCount":98},[],{"trials":846,"activeCount":98},[],{"trials":848,"activeCount":94,"soonestReadout":744},[849],{"nctId":741,"briefTitle":742,"status":154,"phases":850,"primaryCompletion":744,"completion":745,"start":746,"enrollment":747,"conditions":851,"interventions":852},[],[749,750],[752,753,754,755,756,757,758,759,760,761,762],{"intervention":758,"totalTrials":94,"cells":854},{"EARLY_PHASE1":855,"PHASE1":857,"PHASE2":859,"PHASE3":861,"PHASE4":863,"NA":865},{"trials":856,"activeCount":98},[],{"trials":858,"activeCount":98},[],{"trials":860,"activeCount":98},[],{"trials":862,"activeCount":98},[],{"trials":864,"activeCount":98},[],{"trials":866,"activeCount":94,"soonestReadout":744},[867],{"nctId":741,"briefTitle":742,"status":154,"phases":868,"primaryCompletion":744,"completion":745,"start":746,"enrollment":747,"conditions":869,"interventions":870},[],[749,750],[752,753,754,755,756,757,758,759,760,761,762],{"intervention":759,"totalTrials":94,"cells":872},{"EARLY_PHASE1":873,"PHASE1":875,"PHASE2":877,"PHASE3":879,"PHASE4":881,"NA":883},{"trials":874,"activeCount":98},[],{"trials":876,"activeCount":98},[],{"trials":878,"activeCount":98},[],{"trials":880,"activeCount":98},[],{"trials":882,"activeCount":98},[],{"trials":884,"activeCount":94,"soonestReadout":744},[885],{"nctId":741,"briefTitle":742,"status":154,"phases":886,"primaryCompletion":744,"completion":745,"start":746,"enrollment":747,"conditions":887,"interventions":888},[],[749,750],[752,753,754,755,756,757,758,759,760,761,762],{"intervention":760,"totalTrials":94,"cells":890},{"EARLY_PHASE1":891,"PHASE1":893,"PHASE2":895,"PHASE3":897,"PHASE4":899,"NA":901},{"trials":892,"activeCount":98},[],{"trials":894,"activeCount":98},[],{"trials":896,"activeCount":98},[],{"trials":898,"activeCount":98},[],{"trials":900,"activeCount":98},[],{"trials":902,"activeCount":94,"soonestReadout":744},[903],{"nctId":741,"briefTitle":742,"status":154,"phases":904,"primaryCompletion":744,"completion":745,"start":746,"enrollment":747,"conditions":905,"interventions":906},[],[749,750],[752,753,754,755,756,757,758,759,760,761,762],{"intervention":761,"totalTrials":94,"cells":908},{"EARLY_PHASE1":909,"PHASE1":911,"PHASE2":913,"PHASE3":915,"PHASE4":917,"NA":919},{"trials":910,"activeCount":98},[],{"trials":912,"activeCount":98},[],{"trials":914,"activeCount":98},[],{"trials":916,"activeCount":98},[],{"trials":918,"activeCount":98},[],{"trials":920,"activeCount":94,"soonestReadout":744},[921],{"nctId":741,"briefTitle":742,"status":154,"phases":922,"primaryCompletion":744,"completion":745,"start":746,"enrollment":747,"conditions":923,"interventions":924},[],[749,750],[752,753,754,755,756,757,758,759,760,761,762],{"intervention":762,"totalTrials":94,"cells":926},{"EARLY_PHASE1":927,"PHASE1":929,"PHASE2":931,"PHASE3":933,"PHASE4":935,"NA":937},{"trials":928,"activeCount":98},[],{"trials":930,"activeCount":98},[],{"trials":932,"activeCount":98},[],{"trials":934,"activeCount":98},[],{"trials":936,"activeCount":98},[],{"trials":938,"activeCount":94,"soonestReadout":744},[939],{"nctId":741,"briefTitle":742,"status":154,"phases":940,"primaryCompletion":744,"completion":745,"start":746,"enrollment":747,"conditions":941,"interventions":942},[],[749,750],[752,753,754,755,756,757,758,759,760,761,762],{"intervention":944,"totalTrials":200,"cells":945},"Vyvanse",{"EARLY_PHASE1":946,"PHASE1":948,"PHASE2":950,"PHASE3":952,"PHASE4":954,"NA":978},{"trials":947,"activeCount":98},[],{"trials":949,"activeCount":98},[],{"trials":951,"activeCount":98},[],{"trials":953,"activeCount":98},[],{"trials":955,"activeCount":98},[956,967],{"nctId":957,"briefTitle":958,"status":727,"phases":959,"primaryCompletion":960,"completion":961,"start":962,"enrollment":963,"conditions":964,"interventions":966},"NCT01816074","Sequencing Treatments for Mothers With ADHD and Their At - Risk Children",[89],"2016-10","2017-05-01","2012-10",53,[965],"Attention Deficit Hyperactivity Disorder",[944],{"nctId":968,"briefTitle":969,"status":727,"phases":970,"primaryCompletion":971,"completion":971,"start":972,"enrollment":973,"conditions":974,"interventions":976},"NCT02675400","Treatments for Fathers With ADHD and Their At-Risk Children (Fathers Too)",[89],"2018-08-31","2015-12",19,[975],"Attention Deficit\u002FHyperactivity Disorder (ADHD)",[944,977],"Methylphenidate",{"trials":979,"activeCount":98},[],{"intervention":737,"totalTrials":94,"cells":981},{"EARLY_PHASE1":982,"PHASE1":984,"PHASE2":986,"PHASE3":988,"PHASE4":990,"NA":996},{"trials":983,"activeCount":98},[],{"trials":985,"activeCount":98},[],{"trials":987,"activeCount":98},[],{"trials":989,"activeCount":98},[],{"trials":991,"activeCount":98},[992],{"nctId":725,"briefTitle":726,"status":727,"phases":993,"primaryCompletion":729,"completion":729,"start":730,"enrollment":731,"conditions":994,"interventions":995},[89],[733,734,735],[712,737],{"trials":997,"activeCount":98},[],{"intervention":999,"totalTrials":94,"cells":1000},"azithromycin",{"EARLY_PHASE1":1001,"PHASE1":1003,"PHASE2":1005,"PHASE3":1007,"PHASE4":1009,"NA":1021},{"trials":1002,"activeCount":98},[],{"trials":1004,"activeCount":98},[],{"trials":1006,"activeCount":98},[],{"trials":1008,"activeCount":98},[],{"trials":1010,"activeCount":98},[1011],{"nctId":1012,"briefTitle":1013,"status":727,"phases":1014,"primaryCompletion":1015,"completion":1015,"start":1016,"enrollment":1017,"conditions":1018,"interventions":1019},"NCT02677701","Testing the Effect of Adding Chronic Oral Azithromycin to Inhaled Tobramycin in People With Cystic Fibrosis (CF)",[89],"2020-02-13","2016-10-21",119,[18],[999,1020],"inhaled tobramycin",{"trials":1022,"activeCount":98},[],{"intervention":1020,"totalTrials":94,"cells":1024},{"EARLY_PHASE1":1025,"PHASE1":1027,"PHASE2":1029,"PHASE3":1031,"PHASE4":1033,"NA":1039},{"trials":1026,"activeCount":98},[],{"trials":1028,"activeCount":98},[],{"trials":1030,"activeCount":98},[],{"trials":1032,"activeCount":98},[],{"trials":1034,"activeCount":98},[1035],{"nctId":1012,"briefTitle":1013,"status":727,"phases":1036,"primaryCompletion":1015,"completion":1015,"start":1016,"enrollment":1017,"conditions":1037,"interventions":1038},[89],[18],[999,1020],{"trials":1040,"activeCount":98},[],{"intervention":1042,"totalTrials":94,"cells":1043},"Rotarix",{"EARLY_PHASE1":1044,"PHASE1":1046,"PHASE2":1048,"PHASE3":1050,"PHASE4":1052,"NA":1066},{"trials":1045,"activeCount":98},[],{"trials":1047,"activeCount":98},[],{"trials":1049,"activeCount":98},[],{"trials":1051,"activeCount":98},[],{"trials":1053,"activeCount":98},[1054],{"nctId":1055,"briefTitle":1056,"status":727,"phases":1057,"primaryCompletion":1058,"completion":1059,"start":1060,"enrollment":1061,"conditions":1062,"interventions":1065},"NCT00995813","Pilot Study of the Rotavirus Vaccine in Infants With Intestinal Failure",[89],"2012-05","2013-07","2009-12",15,[1063,1064],"Intestinal Failure","Rotavirus Vaccines",[1042],{"trials":1067,"activeCount":98},[],{"intervention":1069,"totalTrials":94,"cells":1070},"Very Low Dose Quillivant XR",{"EARLY_PHASE1":1071,"PHASE1":1073,"PHASE2":1075,"PHASE3":1077,"PHASE4":1079,"NA":1093},{"trials":1072,"activeCount":98},[],{"trials":1074,"activeCount":98},[],{"trials":1076,"activeCount":98},[],{"trials":1078,"activeCount":98},[],{"trials":1080,"activeCount":98},[1081],{"nctId":1082,"briefTitle":1083,"status":727,"phases":1084,"primaryCompletion":1085,"completion":960,"start":1086,"enrollment":11,"conditions":1087,"interventions":1090},"NCT02255565","Dose Response Effects of Quillivant XR in Children With ADHD and Autism: A Pilot Study",[89],"2016-09","2014-09",[1088,1089],"ADHD","Autism",[1069,1091,1092],"Low Dose Quillivant XR","Moderate Dose Quillivant XR",{"trials":1094,"activeCount":98},[],{"intervention":1091,"totalTrials":94,"cells":1096},{"EARLY_PHASE1":1097,"PHASE1":1099,"PHASE2":1101,"PHASE3":1103,"PHASE4":1105,"NA":1111},{"trials":1098,"activeCount":98},[],{"trials":1100,"activeCount":98},[],{"trials":1102,"activeCount":98},[],{"trials":1104,"activeCount":98},[],{"trials":1106,"activeCount":98},[1107],{"nctId":1082,"briefTitle":1083,"status":727,"phases":1108,"primaryCompletion":1085,"completion":960,"start":1086,"enrollment":11,"conditions":1109,"interventions":1110},[89],[1088,1089],[1069,1091,1092],{"trials":1112,"activeCount":98},[],{"intervention":1092,"totalTrials":94,"cells":1114},{"EARLY_PHASE1":1115,"PHASE1":1117,"PHASE2":1119,"PHASE3":1121,"PHASE4":1123,"NA":1129},{"trials":1116,"activeCount":98},[],{"trials":1118,"activeCount":98},[],{"trials":1120,"activeCount":98},[],{"trials":1122,"activeCount":98},[],{"trials":1124,"activeCount":98},[1125],{"nctId":1082,"briefTitle":1083,"status":727,"phases":1126,"primaryCompletion":1085,"completion":960,"start":1086,"enrollment":11,"conditions":1127,"interventions":1128},[89],[1088,1089],[1069,1091,1092],{"trials":1130,"activeCount":98},[],{"intervention":977,"totalTrials":94,"cells":1132},{"EARLY_PHASE1":1133,"PHASE1":1135,"PHASE2":1137,"PHASE3":1139,"PHASE4":1141,"NA":1147},{"trials":1134,"activeCount":98},[],{"trials":1136,"activeCount":98},[],{"trials":1138,"activeCount":98},[],{"trials":1140,"activeCount":98},[],{"trials":1142,"activeCount":98},[1143],{"nctId":968,"briefTitle":969,"status":727,"phases":1144,"primaryCompletion":971,"completion":971,"start":972,"enrollment":973,"conditions":1145,"interventions":1146},[89],[975],[944,977],{"trials":1148,"activeCount":98},[],{"intervention":1150,"totalTrials":200,"cells":1151},"Exenatide",{"EARLY_PHASE1":1152,"PHASE1":1154,"PHASE2":1156,"PHASE3":1172,"PHASE4":1183,"NA":1185},{"trials":1153,"activeCount":98},[],{"trials":1155,"activeCount":98},[],{"trials":1157,"activeCount":98},[1158],{"nctId":1159,"briefTitle":1160,"status":1161,"phases":1162,"primaryCompletion":1163,"completion":1163,"start":962,"enrollment":98,"conditions":1164,"interventions":1170},"NCT01573806","Pharmacology of Exenatide in Pediatric Sepsis","WITHDRAWN",[86,87],"2014-10",[1165,1166,1167,1168,1169],"Septic Shock","Inflammation","Glucose Homeostasis","Organ Dysfunction","Health-related Quality of Life",[1150,1171],"Exenatide vehicle",{"trials":1173,"activeCount":98},[1174],{"nctId":1175,"briefTitle":1176,"status":727,"phases":1177,"primaryCompletion":1178,"completion":1179,"start":1180,"enrollment":187,"conditions":1181,"interventions":1182},"NCT02664441","Energy Balance & Weight Loss in Craniopharyngioma-related or Other Hypothalamic Tumors in Hypothalamic Obesity",[88],"2020-03-16","2020-07-31","2016-03",[161],[1150],{"trials":1184,"activeCount":98},[],{"trials":1186,"activeCount":98},[],{"intervention":1188,"totalTrials":94,"cells":1189},"Dexmethylphenidate",{"EARLY_PHASE1":1190,"PHASE1":1192,"PHASE2":1194,"PHASE3":1196,"PHASE4":1208,"NA":1210},{"trials":1191,"activeCount":98},[],{"trials":1193,"activeCount":98},[],{"trials":1195,"activeCount":98},[],{"trials":1197,"activeCount":98},[1198],{"nctId":1199,"briefTitle":1200,"status":727,"phases":1201,"primaryCompletion":1202,"completion":1202,"start":1203,"enrollment":1204,"conditions":1205,"interventions":1206},"NCT00393042","Sleep and Tolerability Study: Comparing the Effects of Adderall XR and Focalin XR",[88],"2009-02","2006-01",77,[965],[1188,1207],"Mixed Amphetamine Salts, ER",{"trials":1209,"activeCount":98},[],{"trials":1211,"activeCount":98},[],{"intervention":1207,"totalTrials":94,"cells":1213},{"EARLY_PHASE1":1214,"PHASE1":1216,"PHASE2":1218,"PHASE3":1220,"PHASE4":1226,"NA":1228},{"trials":1215,"activeCount":98},[],{"trials":1217,"activeCount":98},[],{"trials":1219,"activeCount":98},[],{"trials":1221,"activeCount":98},[1222],{"nctId":1199,"briefTitle":1200,"status":727,"phases":1223,"primaryCompletion":1202,"completion":1202,"start":1203,"enrollment":1204,"conditions":1224,"interventions":1225},[88],[965],[1188,1207],{"trials":1227,"activeCount":98},[],{"trials":1229,"activeCount":98},[],{"intervention":1231,"totalTrials":94,"cells":1232},"Ketorolac Tromethamine 1 mg\u002Fkg",{"EARLY_PHASE1":1233,"PHASE1":1235,"PHASE2":1237,"PHASE3":1239,"PHASE4":1252,"NA":1254},{"trials":1234,"activeCount":98},[],{"trials":1236,"activeCount":98},[],{"trials":1238,"activeCount":98},[],{"trials":1240,"activeCount":98},[1241],{"nctId":1242,"briefTitle":1243,"status":727,"phases":1244,"primaryCompletion":1245,"completion":1246,"start":1247,"enrollment":1204,"conditions":1248,"interventions":1250},"NCT01260883","Ketorolac in Postoperative Infants: Pharmacokinetics and Safety",[88],"2008-03","2010-12","2000-05",[1249],"Postoperative Pain in Infants",[1231,1251],"Ketorolac Tromethamine 0.5 mg\u002Fkg",{"trials":1253,"activeCount":98},[],{"trials":1255,"activeCount":98},[],{"intervention":1251,"totalTrials":94,"cells":1257},{"EARLY_PHASE1":1258,"PHASE1":1260,"PHASE2":1262,"PHASE3":1264,"PHASE4":1270,"NA":1272},{"trials":1259,"activeCount":98},[],{"trials":1261,"activeCount":98},[],{"trials":1263,"activeCount":98},[],{"trials":1265,"activeCount":98},[1266],{"nctId":1242,"briefTitle":1243,"status":727,"phases":1267,"primaryCompletion":1245,"completion":1246,"start":1247,"enrollment":1204,"conditions":1268,"interventions":1269},[88],[1249],[1231,1251],{"trials":1271,"activeCount":98},[],{"trials":1273,"activeCount":98},[],{"intervention":1275,"totalTrials":94,"cells":1276},"Triostat",{"EARLY_PHASE1":1277,"PHASE1":1279,"PHASE2":1281,"PHASE3":1283,"PHASE4":1295,"NA":1297},{"trials":1278,"activeCount":98},[],{"trials":1280,"activeCount":98},[],{"trials":1282,"activeCount":98},[],{"trials":1284,"activeCount":98},[1285],{"nctId":1286,"briefTitle":1287,"status":727,"phases":1288,"primaryCompletion":1289,"completion":1289,"start":1290,"enrollment":1291,"conditions":1292,"interventions":1294},"NCT02320669","Phase 3 Triiodothyronine Supplementation for Infants After Cardiopulmonary Bypass",[88],"2019-10","2014-11",220,[1293],"Congenital Heart Defects",[1275],{"trials":1296,"activeCount":98},[],{"trials":1298,"activeCount":98},[],{"intervention":1300,"totalTrials":94,"cells":1301},"2005-2006 trivalent inactivated influenza vaccine",{"EARLY_PHASE1":1302,"PHASE1":1304,"PHASE2":1306,"PHASE3":1308,"PHASE4":1321,"NA":1323},{"trials":1303,"activeCount":98},[],{"trials":1305,"activeCount":98},[],{"trials":1307,"activeCount":98},[],{"trials":1309,"activeCount":98},[1310],{"nctId":1311,"briefTitle":1312,"status":727,"phases":1313,"primaryCompletion":1314,"completion":1315,"start":1316,"enrollment":1317,"conditions":1318,"interventions":1320},"NCT00242424","Safety and Immunogenicity of Inactivated Influenza Virus Vaccine Among Healthy Children 6-12 Weeks of Age",[87,88],"2006-09","2007-09","2005-09",1375,[1319],"Inactivated Influenza Vaccine",[1300],{"trials":1322,"activeCount":98},[],{"trials":1324,"activeCount":98},[],{"intervention":1326,"totalTrials":94,"cells":1327},"Prednisolone",{"EARLY_PHASE1":1328,"PHASE1":1330,"PHASE2":1332,"PHASE3":1347,"PHASE4":1349,"NA":1351},{"trials":1329,"activeCount":98},[],{"trials":1331,"activeCount":98},[],{"trials":1333,"activeCount":98},[1334],{"nctId":1335,"briefTitle":1336,"status":1337,"phases":1338,"primaryCompletion":1339,"completion":1340,"start":1341,"enrollment":1342,"conditions":1343,"interventions":1345},"NCT01074437","Corticosteroids With Placebo Versus Corticosteroids With Propranolol Treatment of Infantile Hemangiomas (IH)","TERMINATED",[87],"2012-02","2013-02","2010-02",9,[1344],"Hemangioma",[1326,1346],"Propranolol",{"trials":1348,"activeCount":98},[],{"trials":1350,"activeCount":98},[],{"trials":1352,"activeCount":98},[],{"intervention":1346,"totalTrials":94,"cells":1354},{"EARLY_PHASE1":1355,"PHASE1":1357,"PHASE2":1359,"PHASE3":1365,"PHASE4":1367,"NA":1369},{"trials":1356,"activeCount":98},[],{"trials":1358,"activeCount":98},[],{"trials":1360,"activeCount":98},[1361],{"nctId":1335,"briefTitle":1336,"status":1337,"phases":1362,"primaryCompletion":1339,"completion":1340,"start":1341,"enrollment":1342,"conditions":1363,"interventions":1364},[87],[1344],[1326,1346],{"trials":1366,"activeCount":98},[],{"trials":1368,"activeCount":98},[],{"trials":1370,"activeCount":98},[],{"intervention":1372,"totalTrials":94,"cells":1373},"p52-\u002Fp36- GAP Vaccine",{"EARLY_PHASE1":1374,"PHASE1":1376,"PHASE2":1378,"PHASE3":1390,"PHASE4":1392,"NA":1394},{"trials":1375,"activeCount":98},[],{"trials":1377,"activeCount":98},[],{"trials":1379,"activeCount":98},[1380],{"nctId":1381,"briefTitle":1382,"status":1337,"phases":1383,"primaryCompletion":1384,"completion":1384,"start":1385,"enrollment":19,"conditions":1386,"interventions":1388},"NCT01024686","Phase 1\u002F2a Trial of Pf GAP p52-\u002Fp36- Sporozoite Malaria Vaccine",[86,87],"2011-06","2010-03",[1387],"Malaria",[1372,1389,1372],"p52-p36- GAP Vaccine",{"trials":1391,"activeCount":98},[],{"trials":1393,"activeCount":98},[],{"trials":1395,"activeCount":98},[],{"intervention":1389,"totalTrials":94,"cells":1397},{"EARLY_PHASE1":1398,"PHASE1":1400,"PHASE2":1402,"PHASE3":1408,"PHASE4":1410,"NA":1412},{"trials":1399,"activeCount":98},[],{"trials":1401,"activeCount":98},[],{"trials":1403,"activeCount":98},[1404],{"nctId":1381,"briefTitle":1382,"status":1337,"phases":1405,"primaryCompletion":1384,"completion":1384,"start":1385,"enrollment":19,"conditions":1406,"interventions":1407},[86,87],[1387],[1372,1389,1372],{"trials":1409,"activeCount":98},[],{"trials":1411,"activeCount":98},[],{"trials":1413,"activeCount":98},[],{"intervention":1415,"totalTrials":94,"cells":1416},"Iloprost",{"EARLY_PHASE1":1417,"PHASE1":1419,"PHASE2":1421,"PHASE3":1435,"PHASE4":1437,"NA":1439},{"trials":1418,"activeCount":98},[],{"trials":1420,"activeCount":98},[],{"trials":1422,"activeCount":98},[1423],{"nctId":1424,"briefTitle":1425,"status":1161,"phases":1426,"primaryCompletion":1427,"completion":1427,"start":1428,"enrollment":98,"conditions":1429,"interventions":1434},"NCT00981591","Inhaled Iloprost as an Adjunct to Inhaled Nitric Oxide in Pediatric Critical Care Patients",[86,87],"2013-03","2009-09",[1430,1431,1432,1293,1433],"Pulmonary Hypertension","Neonatal Hypoxic Respiratory Failure","Persistent Pulmonary Hypertension of Newborn","Acute Respiratory Distress Syndrome",[1415],{"trials":1436,"activeCount":98},[],{"trials":1438,"activeCount":98},[],{"trials":1440,"activeCount":98},[],{"intervention":1442,"totalTrials":94,"cells":1443},"Fecal Microbial transplant",{"EARLY_PHASE1":1444,"PHASE1":1446,"PHASE2":1448,"PHASE3":1462,"PHASE4":1464,"NA":1466},{"trials":1445,"activeCount":98},[],{"trials":1447,"activeCount":98},[],{"trials":1449,"activeCount":98},[1450],{"nctId":1451,"briefTitle":1452,"status":1337,"phases":1453,"primaryCompletion":1454,"completion":1454,"start":1455,"enrollment":1456,"conditions":1457,"interventions":1459},"NCT02272868","Fecal Microbial Transplant in Pediatric Crohn's Disease",[86,87],"2016-10-01","2015-01",7,[1458],"Crohn's Disease",[1442,1460,1461],"Normal Saline","rifaximin+omeprazole+miralax",{"trials":1463,"activeCount":98},[],{"trials":1465,"activeCount":98},[],{"trials":1467,"activeCount":98},[],{"intervention":1460,"totalTrials":94,"cells":1469},{"EARLY_PHASE1":1470,"PHASE1":1472,"PHASE2":1474,"PHASE3":1480,"PHASE4":1482,"NA":1484},{"trials":1471,"activeCount":98},[],{"trials":1473,"activeCount":98},[],{"trials":1475,"activeCount":98},[1476],{"nctId":1451,"briefTitle":1452,"status":1337,"phases":1477,"primaryCompletion":1454,"completion":1454,"start":1455,"enrollment":1456,"conditions":1478,"interventions":1479},[86,87],[1458],[1442,1460,1461],{"trials":1481,"activeCount":98},[],{"trials":1483,"activeCount":98},[],{"trials":1485,"activeCount":98},[],{"intervention":1461,"totalTrials":94,"cells":1487},{"EARLY_PHASE1":1488,"PHASE1":1490,"PHASE2":1492,"PHASE3":1498,"PHASE4":1500,"NA":1502},{"trials":1489,"activeCount":98},[],{"trials":1491,"activeCount":98},[],{"trials":1493,"activeCount":98},[1494],{"nctId":1451,"briefTitle":1452,"status":1337,"phases":1495,"primaryCompletion":1454,"completion":1454,"start":1455,"enrollment":1456,"conditions":1496,"interventions":1497},[86,87],[1458],[1442,1460,1461],{"trials":1499,"activeCount":98},[],{"trials":1501,"activeCount":98},[],{"trials":1503,"activeCount":98},[],{"intervention":1505,"totalTrials":94,"cells":1506},"Tobramycin solution for inhalation",{"EARLY_PHASE1":1507,"PHASE1":1509,"PHASE2":1511,"PHASE3":1526,"PHASE4":1528,"NA":1530},{"trials":1508,"activeCount":98},[],{"trials":1510,"activeCount":98},[],{"trials":1512,"activeCount":98},[1513],{"nctId":1514,"briefTitle":1515,"status":727,"phases":1516,"primaryCompletion":1517,"completion":1518,"start":1519,"enrollment":1520,"conditions":1521,"interventions":1523},"NCT00097773","Comparison of Two Treatment Regimens to Reduce PA Infection in Children With Cystic Fibrosis",[87],"2009-06","2009-08","2004-09",304,[18,1522],"Pulmonary Disease, Chronic Obstructive",[1505,1524,1525],"Oral placebo","Oral ciprofloxacin",{"trials":1527,"activeCount":98},[],{"trials":1529,"activeCount":98},[],{"trials":1531,"activeCount":98},[],{"intervention":1524,"totalTrials":94,"cells":1533},{"EARLY_PHASE1":1534,"PHASE1":1536,"PHASE2":1538,"PHASE3":1544,"PHASE4":1546,"NA":1548},{"trials":1535,"activeCount":98},[],{"trials":1537,"activeCount":98},[],{"trials":1539,"activeCount":98},[1540],{"nctId":1514,"briefTitle":1515,"status":727,"phases":1541,"primaryCompletion":1517,"completion":1518,"start":1519,"enrollment":1520,"conditions":1542,"interventions":1543},[87],[18,1522],[1505,1524,1525],{"trials":1545,"activeCount":98},[],{"trials":1547,"activeCount":98},[],{"trials":1549,"activeCount":98},[],{"intervention":1525,"totalTrials":94,"cells":1551},{"EARLY_PHASE1":1552,"PHASE1":1554,"PHASE2":1556,"PHASE3":1562,"PHASE4":1564,"NA":1566},{"trials":1553,"activeCount":98},[],{"trials":1555,"activeCount":98},[],{"trials":1557,"activeCount":98},[1558],{"nctId":1514,"briefTitle":1515,"status":727,"phases":1559,"primaryCompletion":1517,"completion":1518,"start":1519,"enrollment":1520,"conditions":1560,"interventions":1561},[87],[18,1522],[1505,1524,1525],{"trials":1563,"activeCount":98},[],{"trials":1565,"activeCount":98},[],{"trials":1567,"activeCount":98},[],{"intervention":1171,"totalTrials":94,"cells":1569},{"EARLY_PHASE1":1570,"PHASE1":1572,"PHASE2":1574,"PHASE3":1580,"PHASE4":1582,"NA":1584},{"trials":1571,"activeCount":98},[],{"trials":1573,"activeCount":98},[],{"trials":1575,"activeCount":98},[1576],{"nctId":1159,"briefTitle":1160,"status":1161,"phases":1577,"primaryCompletion":1163,"completion":1163,"start":962,"enrollment":98,"conditions":1578,"interventions":1579},[86,87],[1165,1166,1167,1168,1169],[1150,1171],{"trials":1581,"activeCount":98},[],{"trials":1583,"activeCount":98},[],{"trials":1585,"activeCount":98},[],{"intervention":1587,"totalTrials":94,"cells":1588},"Plerixafor Dose Escalation",{"EARLY_PHASE1":1589,"PHASE1":1591,"PHASE2":1608,"PHASE3":1610,"PHASE4":1612,"NA":1614},{"trials":1590,"activeCount":98},[],{"trials":1592,"activeCount":98},[1593],{"nctId":1594,"briefTitle":1595,"status":727,"phases":1596,"primaryCompletion":1597,"completion":1598,"start":1599,"enrollment":699,"conditions":1600,"interventions":1607},"NCT01319864","POETIC Plerixafor as a Chemosensitizing Agent for Relapsed Acute Leukemia and MDS in Pediatric Patients",[86],"2013-06-28","2016-06-28","2011-03",[1601,1602,1603,1604,1605,1606],"Relapsed\u002FRefractory AML","Relapsed\u002FRefractory ALL","Secondary AML\u002FMDS","Acute Leukemia of Ambiguous Lineage","AML","ALL",[1587],{"trials":1609,"activeCount":98},[],{"trials":1611,"activeCount":98},[],{"trials":1613,"activeCount":98},[],{"trials":1615,"activeCount":98},[],{"intervention":1617,"totalTrials":94,"cells":1618},"Tissue plasminogen activator",{"EARLY_PHASE1":1619,"PHASE1":1621,"PHASE2":1631,"PHASE3":1633,"PHASE4":1635,"NA":1637},{"trials":1620,"activeCount":98},[],{"trials":1622,"activeCount":98},[1623],{"nctId":1624,"briefTitle":1625,"status":1337,"phases":1626,"primaryCompletion":1627,"completion":1627,"start":962,"enrollment":94,"conditions":1628,"interventions":1630},"NCT01591096","Thrombolysis in Pediatric Stroke (TIPS)",[86],"2013-12",[1629],"Stroke",[1617],{"trials":1632,"activeCount":98},[],{"trials":1634,"activeCount":98},[],{"trials":1636,"activeCount":98},[],{"trials":1638,"activeCount":98},[],{"intervention":1640,"totalTrials":94,"cells":1641},"Malaria challenge",{"EARLY_PHASE1":1642,"PHASE1":1644,"PHASE2":1655,"PHASE3":1657,"PHASE4":1659,"NA":1661},{"trials":1643,"activeCount":98},[],{"trials":1645,"activeCount":98},[1646],{"nctId":1647,"briefTitle":1648,"status":727,"phases":1649,"primaryCompletion":1650,"completion":1651,"start":1341,"enrollment":19,"conditions":1652,"interventions":1654},"NCT01058226","Reproducibility of Malaria Challenge in Healthy Volunteers",[86],"2010-05","2010-09",[1653],"Healthy",[1640],{"trials":1656,"activeCount":98},[],{"trials":1658,"activeCount":98},[],{"trials":1660,"activeCount":98},[],{"trials":1662,"activeCount":98},[],{"intervention":1664,"totalTrials":94,"cells":1665},"filgrastim",{"EARLY_PHASE1":1666,"PHASE1":1668,"PHASE2":1684,"PHASE3":1686,"PHASE4":1688,"NA":1690},{"trials":1667,"activeCount":98},[],{"trials":1669,"activeCount":98},[1670],{"nctId":1671,"briefTitle":1672,"status":1337,"phases":1673,"primaryCompletion":1674,"completion":1674,"start":1675,"enrollment":159,"conditions":1676,"interventions":1678},"NCT00003194","Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory Solid Tumors",[86],"2002-12-19","1997-07",[1677],"Unspecified Childhood Solid Tumor, Protocol Specific",[1664,1679,1680,1681,1682,1683],"carboplatin","cyclophosphamide","etoposide","thiotepa","topotecan hydrochloride",{"trials":1685,"activeCount":98},[],{"trials":1687,"activeCount":98},[],{"trials":1689,"activeCount":98},[],{"trials":1691,"activeCount":98},[],{"intervention":1679,"totalTrials":94,"cells":1693},{"EARLY_PHASE1":1694,"PHASE1":1696,"PHASE2":1702,"PHASE3":1704,"PHASE4":1706,"NA":1708},{"trials":1695,"activeCount":98},[],{"trials":1697,"activeCount":98},[1698],{"nctId":1671,"briefTitle":1672,"status":1337,"phases":1699,"primaryCompletion":1674,"completion":1674,"start":1675,"enrollment":159,"conditions":1700,"interventions":1701},[86],[1677],[1664,1679,1680,1681,1682,1683],{"trials":1703,"activeCount":98},[],{"trials":1705,"activeCount":98},[],{"trials":1707,"activeCount":98},[],{"trials":1709,"activeCount":98},[],{"intervention":1680,"totalTrials":94,"cells":1711},{"EARLY_PHASE1":1712,"PHASE1":1714,"PHASE2":1720,"PHASE3":1722,"PHASE4":1724,"NA":1726},{"trials":1713,"activeCount":98},[],{"trials":1715,"activeCount":98},[1716],{"nctId":1671,"briefTitle":1672,"status":1337,"phases":1717,"primaryCompletion":1674,"completion":1674,"start":1675,"enrollment":159,"conditions":1718,"interventions":1719},[86],[1677],[1664,1679,1680,1681,1682,1683],{"trials":1721,"activeCount":98},[],{"trials":1723,"activeCount":98},[],{"trials":1725,"activeCount":98},[],{"trials":1727,"activeCount":98},[],{"intervention":1682,"totalTrials":94,"cells":1729},{"EARLY_PHASE1":1730,"PHASE1":1732,"PHASE2":1738,"PHASE3":1740,"PHASE4":1742,"NA":1744},{"trials":1731,"activeCount":98},[],{"trials":1733,"activeCount":98},[1734],{"nctId":1671,"briefTitle":1672,"status":1337,"phases":1735,"primaryCompletion":1674,"completion":1674,"start":1675,"enrollment":159,"conditions":1736,"interventions":1737},[86],[1677],[1664,1679,1680,1681,1682,1683],{"trials":1739,"activeCount":98},[],{"trials":1741,"activeCount":98},[],{"trials":1743,"activeCount":98},[],{"trials":1745,"activeCount":98},[],{"intervention":1683,"totalTrials":94,"cells":1747},{"EARLY_PHASE1":1748,"PHASE1":1750,"PHASE2":1756,"PHASE3":1758,"PHASE4":1760,"NA":1762},{"trials":1749,"activeCount":98},[],{"trials":1751,"activeCount":98},[1752],{"nctId":1671,"briefTitle":1672,"status":1337,"phases":1753,"primaryCompletion":1674,"completion":1674,"start":1675,"enrollment":159,"conditions":1754,"interventions":1755},[86],[1677],[1664,1679,1680,1681,1682,1683],{"trials":1757,"activeCount":98},[],{"trials":1759,"activeCount":98},[],{"trials":1761,"activeCount":98},[],{"trials":1763,"activeCount":98},[],{"intervention":1765,"totalTrials":94,"cells":1766},"Curcumin",{"EARLY_PHASE1":1767,"PHASE1":1769,"PHASE2":1781,"PHASE3":1783,"PHASE4":1785,"NA":1787},{"trials":1768,"activeCount":98},[],{"trials":1770,"activeCount":98},[1771],{"nctId":1772,"briefTitle":1773,"status":727,"phases":1774,"primaryCompletion":1775,"completion":1775,"start":1776,"enrollment":16,"conditions":1777,"interventions":1780},"NCT00889161","Curcumin in Pediatric Inflammatory Bowel Disease",[86],"2010-06","2009-05",[1778,1779,1458],"Inflammatory Bowel Disease","Ulcerative Colitis",[1765],{"trials":1782,"activeCount":98},[],{"trials":1784,"activeCount":98},[],{"trials":1786,"activeCount":98},[],{"trials":1788,"activeCount":98},[],{"intervention":1790,"totalTrials":94,"cells":1791},"EGFR806-specific chimeric antigen receptor (CAR) T cell",{"EARLY_PHASE1":1792,"PHASE1":1794,"PHASE2":1804,"PHASE3":1806,"PHASE4":1808,"NA":1810},{"trials":1793,"activeCount":98},[],{"trials":1795,"activeCount":98},[1796],{"nctId":1797,"briefTitle":1798,"status":727,"phases":1799,"primaryCompletion":1800,"completion":1800,"start":1801,"enrollment":16,"conditions":1802,"interventions":1803},"NCT03638167","EGFR806-specific CAR T Cell Locoregional Immunotherapy for EGFR-positive Recurrent or Refractory Pediatric CNS Tumors",[86],"2023-12-22","2019-03-19",[560,510,504,561,25,506,507,508,562],[1790],{"trials":1805,"activeCount":98},[],{"trials":1807,"activeCount":98},[],{"trials":1809,"activeCount":98},[],{"trials":1811,"activeCount":98},[],{"intervention":1813,"totalTrials":94,"cells":1814},"GAP3KO",{"EARLY_PHASE1":1815,"PHASE1":1817,"PHASE2":1828,"PHASE3":1830,"PHASE4":1832,"NA":1834},{"trials":1816,"activeCount":98},[],{"trials":1818,"activeCount":98},[1819],{"nctId":1820,"briefTitle":1821,"status":727,"phases":1822,"primaryCompletion":1823,"completion":1824,"start":1825,"enrollment":558,"conditions":1826,"interventions":1827},"NCT02313376","Safety, Attenuation and Immunogenicity of GAP3KO Administered Via A Stephensi Mosquitoes",[86],"2015-02","2015-08","2014-12",[1387],[1813],{"trials":1829,"activeCount":98},[],{"trials":1831,"activeCount":98},[],{"trials":1833,"activeCount":98},[],{"trials":1835,"activeCount":98},[],{"intervention":1837,"totalTrials":94,"cells":1838},"P. falciparum infection",{"EARLY_PHASE1":1839,"PHASE1":1841,"PHASE2":1854,"PHASE3":1856,"PHASE4":1858,"NA":1860},{"trials":1840,"activeCount":98},[],{"trials":1842,"activeCount":98},[1843],{"nctId":1844,"briefTitle":1845,"status":727,"phases":1846,"primaryCompletion":1847,"completion":1848,"start":1849,"enrollment":11,"conditions":1850,"interventions":1851},"NCT01500980","Malaria Challenge in Healthy Volunteers",[86],"2012-07","2012-11","2011-12",[1387],[1837,1852,1853,1853],"Chloroquine","Primaquine",{"trials":1855,"activeCount":98},[],{"trials":1857,"activeCount":98},[],{"trials":1859,"activeCount":98},[],{"trials":1861,"activeCount":98},[],{"intervention":1852,"totalTrials":94,"cells":1863},{"EARLY_PHASE1":1864,"PHASE1":1866,"PHASE2":1872,"PHASE3":1874,"PHASE4":1876,"NA":1878},{"trials":1865,"activeCount":98},[],{"trials":1867,"activeCount":98},[1868],{"nctId":1844,"briefTitle":1845,"status":727,"phases":1869,"primaryCompletion":1847,"completion":1848,"start":1849,"enrollment":11,"conditions":1870,"interventions":1871},[86],[1387],[1837,1852,1853,1853],{"trials":1873,"activeCount":98},[],{"trials":1875,"activeCount":98},[],{"trials":1877,"activeCount":98},[],{"trials":1879,"activeCount":98},[],{"intervention":1853,"totalTrials":94,"cells":1881},{"EARLY_PHASE1":1882,"PHASE1":1884,"PHASE2":1890,"PHASE3":1892,"PHASE4":1894,"NA":1896},{"trials":1883,"activeCount":98},[],{"trials":1885,"activeCount":98},[1886],{"nctId":1844,"briefTitle":1845,"status":727,"phases":1887,"primaryCompletion":1847,"completion":1848,"start":1849,"enrollment":11,"conditions":1888,"interventions":1889},[86],[1387],[1837,1852,1853,1853],{"trials":1891,"activeCount":98},[],{"trials":1893,"activeCount":98},[],{"trials":1895,"activeCount":98},[],{"trials":1897,"activeCount":98},[],{"intervention":1899,"totalTrials":94,"cells":1900},"ABI-009",{"EARLY_PHASE1":1901,"PHASE1":1903,"PHASE2":1916,"PHASE3":1918,"PHASE4":1920,"NA":1922},{"trials":1902,"activeCount":98},[],{"trials":1904,"activeCount":98},[1905],{"nctId":1906,"briefTitle":1907,"status":727,"phases":1908,"primaryCompletion":1909,"completion":1910,"start":1911,"enrollment":1912,"conditions":1913,"interventions":1915},"NCT03646240","ABI-009 (Nab-rapamycin) for Surgically-Refractory Epilepsy (RaSuRE)",[86],"2022-08-22","2022-12-31","2018-07-31",14,[1914],"Epilepsy Intractable",[1899],{"trials":1917,"activeCount":98},[],{"trials":1919,"activeCount":98},[],{"trials":1921,"activeCount":98},[],{"trials":1923,"activeCount":98},[],{"intervention":1925,"totalTrials":94,"cells":1926},"Dexmedetomidine",{"EARLY_PHASE1":1927,"PHASE1":1938,"PHASE2":1940,"PHASE3":1942,"PHASE4":1944,"NA":1946},{"trials":1928,"activeCount":98},[1929],{"nctId":1930,"briefTitle":1931,"status":727,"phases":1932,"primaryCompletion":1933,"completion":1934,"start":1180,"enrollment":1456,"conditions":1935,"interventions":1937},"NCT02529202","Dexmedetomidine Pharmacokinetics in Neonates During Therapeutic Hypothermia",[85],"2016-11","2017-01",[1936],"Hypoxic-ischemic Encephalopathy",[1925],{"trials":1939,"activeCount":98},[],{"trials":1941,"activeCount":98},[],{"trials":1943,"activeCount":98},[],{"trials":1945,"activeCount":98},[],{"trials":1947,"activeCount":98},[],{"intervention":1949,"totalTrials":200,"cells":1950},"Morphine",{"EARLY_PHASE1":1951,"PHASE1":1953,"PHASE2":1955,"PHASE3":1957,"PHASE4":1959,"NA":1961},{"trials":1952,"activeCount":98},[],{"trials":1954,"activeCount":98},[],{"trials":1956,"activeCount":98},[],{"trials":1958,"activeCount":98},[],{"trials":1960,"activeCount":98},[],{"trials":1962,"activeCount":98},[1963,1980],{"nctId":1964,"briefTitle":1965,"status":1337,"phases":1966,"primaryCompletion":1967,"completion":1967,"start":1968,"enrollment":187,"conditions":1969,"interventions":1972},"NCT03435692","Post Operative Pain Control After Pediatric Hip Surgery",[90],"2014-07-29","2011-07-15",[1970,1971],"Hip Surgery","Post Operative Pain Control",[1973,1949,1974,1975,1976,1977,1978,1979],"Fentanyl","Lorazepam","Ondansetron","Diphenhydramine","Acetaminophen","Oxycodone","Ropivacaine",{"nctId":1981,"briefTitle":1982,"status":727,"phases":1983,"completion":1984,"start":1985,"enrollment":1986,"conditions":1987,"interventions":1990},"NCT00004696","Study of Morphine in Postoperative Infants to Allow Normal Ventilation",[90],"1998-07","1994-08",100,[1988,1989],"Infant, Newborn, Diseases","Pain",[1991],"morphine",{"intervention":1681,"totalTrials":200,"cells":1993},{"EARLY_PHASE1":1994,"PHASE1":1996,"PHASE2":2002,"PHASE3":2004,"PHASE4":2006,"NA":2008},{"trials":1995,"activeCount":98},[],{"trials":1997,"activeCount":98},[1998],{"nctId":1671,"briefTitle":1672,"status":1337,"phases":1999,"primaryCompletion":1674,"completion":1674,"start":1675,"enrollment":159,"conditions":2000,"interventions":2001},[86],[1677],[1664,1679,1680,1681,1682,1683],{"trials":2003,"activeCount":98},[],{"trials":2005,"activeCount":98},[],{"trials":2007,"activeCount":98},[],{"trials":2009,"activeCount":98},[2010],{"nctId":2011,"briefTitle":2012,"status":2013,"phases":2014,"primaryCompletion":1933,"completion":2015,"start":1627,"enrollment":699,"conditions":2016,"interventions":2018},"NCT02015728","Selecting Patient-Specific Biologically Targeted Therapy for Pediatric Patients With Refractory Or Recurrent Brain Tumors","UNKNOWN",[90],"2017-12",[2017],"Recurrent Childhood Brain Tumor",[2019,2020,2021,2022,2023,2024],"Temozolomide","Etoposide","Sorafenib","Everolimus","Erlotinib","Dasatinib",{"intervention":1973,"totalTrials":94,"cells":2026},{"EARLY_PHASE1":2027,"PHASE1":2029,"PHASE2":2031,"PHASE3":2033,"PHASE4":2035,"NA":2037},{"trials":2028,"activeCount":98},[],{"trials":2030,"activeCount":98},[],{"trials":2032,"activeCount":98},[],{"trials":2034,"activeCount":98},[],{"trials":2036,"activeCount":98},[],{"trials":2038,"activeCount":98},[2039],{"nctId":1964,"briefTitle":1965,"status":1337,"phases":2040,"primaryCompletion":1967,"completion":1967,"start":1968,"enrollment":187,"conditions":2041,"interventions":2042},[90],[1970,1971],[1973,1949,1974,1975,1976,1977,1978,1979],{"intervention":1974,"totalTrials":94,"cells":2044},{"EARLY_PHASE1":2045,"PHASE1":2047,"PHASE2":2049,"PHASE3":2051,"PHASE4":2053,"NA":2055},{"trials":2046,"activeCount":98},[],{"trials":2048,"activeCount":98},[],{"trials":2050,"activeCount":98},[],{"trials":2052,"activeCount":98},[],{"trials":2054,"activeCount":98},[],{"trials":2056,"activeCount":98},[2057],{"nctId":1964,"briefTitle":1965,"status":1337,"phases":2058,"primaryCompletion":1967,"completion":1967,"start":1968,"enrollment":187,"conditions":2059,"interventions":2060},[90],[1970,1971],[1973,1949,1974,1975,1976,1977,1978,1979],{"intervention":1975,"totalTrials":94,"cells":2062},{"EARLY_PHASE1":2063,"PHASE1":2065,"PHASE2":2067,"PHASE3":2069,"PHASE4":2071,"NA":2073},{"trials":2064,"activeCount":98},[],{"trials":2066,"activeCount":98},[],{"trials":2068,"activeCount":98},[],{"trials":2070,"activeCount":98},[],{"trials":2072,"activeCount":98},[],{"trials":2074,"activeCount":98},[2075],{"nctId":1964,"briefTitle":1965,"status":1337,"phases":2076,"primaryCompletion":1967,"completion":1967,"start":1968,"enrollment":187,"conditions":2077,"interventions":2078},[90],[1970,1971],[1973,1949,1974,1975,1976,1977,1978,1979],{"intervention":1976,"totalTrials":94,"cells":2080},{"EARLY_PHASE1":2081,"PHASE1":2083,"PHASE2":2085,"PHASE3":2087,"PHASE4":2089,"NA":2091},{"trials":2082,"activeCount":98},[],{"trials":2084,"activeCount":98},[],{"trials":2086,"activeCount":98},[],{"trials":2088,"activeCount":98},[],{"trials":2090,"activeCount":98},[],{"trials":2092,"activeCount":98},[2093],{"nctId":1964,"briefTitle":1965,"status":1337,"phases":2094,"primaryCompletion":1967,"completion":1967,"start":1968,"enrollment":187,"conditions":2095,"interventions":2096},[90],[1970,1971],[1973,1949,1974,1975,1976,1977,1978,1979],{"intervention":1977,"totalTrials":94,"cells":2098},{"EARLY_PHASE1":2099,"PHASE1":2101,"PHASE2":2103,"PHASE3":2105,"PHASE4":2107,"NA":2109},{"trials":2100,"activeCount":98},[],{"trials":2102,"activeCount":98},[],{"trials":2104,"activeCount":98},[],{"trials":2106,"activeCount":98},[],{"trials":2108,"activeCount":98},[],{"trials":2110,"activeCount":98},[2111],{"nctId":1964,"briefTitle":1965,"status":1337,"phases":2112,"primaryCompletion":1967,"completion":1967,"start":1968,"enrollment":187,"conditions":2113,"interventions":2114},[90],[1970,1971],[1973,1949,1974,1975,1976,1977,1978,1979],{"intervention":1978,"totalTrials":94,"cells":2116},{"EARLY_PHASE1":2117,"PHASE1":2119,"PHASE2":2121,"PHASE3":2123,"PHASE4":2125,"NA":2127},{"trials":2118,"activeCount":98},[],{"trials":2120,"activeCount":98},[],{"trials":2122,"activeCount":98},[],{"trials":2124,"activeCount":98},[],{"trials":2126,"activeCount":98},[],{"trials":2128,"activeCount":98},[2129],{"nctId":1964,"briefTitle":1965,"status":1337,"phases":2130,"primaryCompletion":1967,"completion":1967,"start":1968,"enrollment":187,"conditions":2131,"interventions":2132},[90],[1970,1971],[1973,1949,1974,1975,1976,1977,1978,1979],{"intervention":1979,"totalTrials":94,"cells":2134},{"EARLY_PHASE1":2135,"PHASE1":2137,"PHASE2":2139,"PHASE3":2141,"PHASE4":2143,"NA":2145},{"trials":2136,"activeCount":98},[],{"trials":2138,"activeCount":98},[],{"trials":2140,"activeCount":98},[],{"trials":2142,"activeCount":98},[],{"trials":2144,"activeCount":98},[],{"trials":2146,"activeCount":98},[2147],{"nctId":1964,"briefTitle":1965,"status":1337,"phases":2148,"primaryCompletion":1967,"completion":1967,"start":1968,"enrollment":187,"conditions":2149,"interventions":2150},[90],[1970,1971],[1973,1949,1974,1975,1976,1977,1978,1979],{"intervention":2152,"totalTrials":94,"cells":2153},"Aerosolized Intranasal midazolam",{"EARLY_PHASE1":2154,"PHASE1":2156,"PHASE2":2158,"PHASE3":2160,"PHASE4":2162,"NA":2164},{"trials":2155,"activeCount":98},[],{"trials":2157,"activeCount":98},[],{"trials":2159,"activeCount":98},[],{"trials":2161,"activeCount":98},[],{"trials":2163,"activeCount":98},[],{"trials":2165,"activeCount":98},[2166],{"nctId":2167,"briefTitle":2168,"status":727,"phases":2169,"primaryCompletion":1060,"completion":2170,"start":2171,"enrollment":2172,"conditions":2173,"interventions":2175},"NCT00675909","Improving Sedation of Children Undergoing Procedures in the Emergency Department",[90],"2010-01","2006-11",180,[2174],"Anxiety",[2152,2176,2177],"Aerosolized Buccal Midazolam","Oral midazolam",{"intervention":2176,"totalTrials":94,"cells":2179},{"EARLY_PHASE1":2180,"PHASE1":2182,"PHASE2":2184,"PHASE3":2186,"PHASE4":2188,"NA":2190},{"trials":2181,"activeCount":98},[],{"trials":2183,"activeCount":98},[],{"trials":2185,"activeCount":98},[],{"trials":2187,"activeCount":98},[],{"trials":2189,"activeCount":98},[],{"trials":2191,"activeCount":98},[2192],{"nctId":2167,"briefTitle":2168,"status":727,"phases":2193,"primaryCompletion":1060,"completion":2170,"start":2171,"enrollment":2172,"conditions":2194,"interventions":2195},[90],[2174],[2152,2176,2177],{"intervention":2177,"totalTrials":94,"cells":2197},{"EARLY_PHASE1":2198,"PHASE1":2200,"PHASE2":2202,"PHASE3":2204,"PHASE4":2206,"NA":2208},{"trials":2199,"activeCount":98},[],{"trials":2201,"activeCount":98},[],{"trials":2203,"activeCount":98},[],{"trials":2205,"activeCount":98},[],{"trials":2207,"activeCount":98},[],{"trials":2209,"activeCount":98},[2210],{"nctId":2167,"briefTitle":2168,"status":727,"phases":2211,"primaryCompletion":1060,"completion":2170,"start":2171,"enrollment":2172,"conditions":2212,"interventions":2213},[90],[2174],[2152,2176,2177],{"intervention":2215,"totalTrials":94,"cells":2216},"Aristospan 20mg",{"EARLY_PHASE1":2217,"PHASE1":2219,"PHASE2":2221,"PHASE3":2223,"PHASE4":2225,"NA":2227},{"trials":2218,"activeCount":98},[],{"trials":2220,"activeCount":98},[],{"trials":2222,"activeCount":98},[],{"trials":2224,"activeCount":98},[],{"trials":2226,"activeCount":98},[],{"trials":2228,"activeCount":98},[2229],{"nctId":2230,"briefTitle":2231,"status":1337,"phases":2232,"primaryCompletion":2233,"completion":2234,"start":2235,"enrollment":2236,"conditions":2237,"interventions":2239},"NCT01026909","Intraarticular Corticosteroid Therapy in Perthes Disease.",[90],"2013-10","2014-01","2009-03",3,[2238],"Legg-Calve Perthes Disease",[2215],{"intervention":2241,"totalTrials":94,"cells":2242},"IV amikacin",{"EARLY_PHASE1":2243,"PHASE1":2245,"PHASE2":2247,"PHASE3":2249,"PHASE4":2251,"NA":2253},{"trials":2244,"activeCount":98},[],{"trials":2246,"activeCount":98},[],{"trials":2248,"activeCount":98},[],{"trials":2250,"activeCount":98},[],{"trials":2252,"activeCount":98},[],{"trials":2254,"activeCount":98},[2255],{"nctId":2256,"briefTitle":2257,"status":727,"phases":2258,"completion":2259,"start":2260,"enrollment":2261,"conditions":2262,"interventions":2264},"NCT00153634","Standard vs. Biofilm Susceptibility Testing in Cystic Fibrosis (CF)",[90],"2007-11","2004-03",75,[18,2263],"Chronic Bronchitis",[2241,2265,2266,2267,2268,2269,2270,2271],"PO azithromycin","IV ceftazidime","PO ciprofloxacin","IV meropenem","IV piperacillin-tazobactam","IV ticarcillin-clavulanate","IV tobramycin",{"intervention":2265,"totalTrials":94,"cells":2273},{"EARLY_PHASE1":2274,"PHASE1":2276,"PHASE2":2278,"PHASE3":2280,"PHASE4":2282,"NA":2284},{"trials":2275,"activeCount":98},[],{"trials":2277,"activeCount":98},[],{"trials":2279,"activeCount":98},[],{"trials":2281,"activeCount":98},[],{"trials":2283,"activeCount":98},[],{"trials":2285,"activeCount":98},[2286],{"nctId":2256,"briefTitle":2257,"status":727,"phases":2287,"completion":2259,"start":2260,"enrollment":2261,"conditions":2288,"interventions":2289},[90],[18,2263],[2241,2265,2266,2267,2268,2269,2270,2271],{"intervention":2266,"totalTrials":94,"cells":2291},{"EARLY_PHASE1":2292,"PHASE1":2294,"PHASE2":2296,"PHASE3":2298,"PHASE4":2300,"NA":2302},{"trials":2293,"activeCount":98},[],{"trials":2295,"activeCount":98},[],{"trials":2297,"activeCount":98},[],{"trials":2299,"activeCount":98},[],{"trials":2301,"activeCount":98},[],{"trials":2303,"activeCount":98},[2304],{"nctId":2256,"briefTitle":2257,"status":727,"phases":2305,"completion":2259,"start":2260,"enrollment":2261,"conditions":2306,"interventions":2307},[90],[18,2263],[2241,2265,2266,2267,2268,2269,2270,2271],{"intervention":2267,"totalTrials":94,"cells":2309},{"EARLY_PHASE1":2310,"PHASE1":2312,"PHASE2":2314,"PHASE3":2316,"PHASE4":2318,"NA":2320},{"trials":2311,"activeCount":98},[],{"trials":2313,"activeCount":98},[],{"trials":2315,"activeCount":98},[],{"trials":2317,"activeCount":98},[],{"trials":2319,"activeCount":98},[],{"trials":2321,"activeCount":98},[2322],{"nctId":2256,"briefTitle":2257,"status":727,"phases":2323,"completion":2259,"start":2260,"enrollment":2261,"conditions":2324,"interventions":2325},[90],[18,2263],[2241,2265,2266,2267,2268,2269,2270,2271],{"intervention":2268,"totalTrials":94,"cells":2327},{"EARLY_PHASE1":2328,"PHASE1":2330,"PHASE2":2332,"PHASE3":2334,"PHASE4":2336,"NA":2338},{"trials":2329,"activeCount":98},[],{"trials":2331,"activeCount":98},[],{"trials":2333,"activeCount":98},[],{"trials":2335,"activeCount":98},[],{"trials":2337,"activeCount":98},[],{"trials":2339,"activeCount":98},[2340],{"nctId":2256,"briefTitle":2257,"status":727,"phases":2341,"completion":2259,"start":2260,"enrollment":2261,"conditions":2342,"interventions":2343},[90],[18,2263],[2241,2265,2266,2267,2268,2269,2270,2271],{"intervention":2269,"totalTrials":94,"cells":2345},{"EARLY_PHASE1":2346,"PHASE1":2348,"PHASE2":2350,"PHASE3":2352,"PHASE4":2354,"NA":2356},{"trials":2347,"activeCount":98},[],{"trials":2349,"activeCount":98},[],{"trials":2351,"activeCount":98},[],{"trials":2353,"activeCount":98},[],{"trials":2355,"activeCount":98},[],{"trials":2357,"activeCount":98},[2358],{"nctId":2256,"briefTitle":2257,"status":727,"phases":2359,"completion":2259,"start":2260,"enrollment":2261,"conditions":2360,"interventions":2361},[90],[18,2263],[2241,2265,2266,2267,2268,2269,2270,2271],{"intervention":2270,"totalTrials":94,"cells":2363},{"EARLY_PHASE1":2364,"PHASE1":2366,"PHASE2":2368,"PHASE3":2370,"PHASE4":2372,"NA":2374},{"trials":2365,"activeCount":98},[],{"trials":2367,"activeCount":98},[],{"trials":2369,"activeCount":98},[],{"trials":2371,"activeCount":98},[],{"trials":2373,"activeCount":98},[],{"trials":2375,"activeCount":98},[2376],{"nctId":2256,"briefTitle":2257,"status":727,"phases":2377,"completion":2259,"start":2260,"enrollment":2261,"conditions":2378,"interventions":2379},[90],[18,2263],[2241,2265,2266,2267,2268,2269,2270,2271],{"intervention":2271,"totalTrials":94,"cells":2381},{"EARLY_PHASE1":2382,"PHASE1":2384,"PHASE2":2386,"PHASE3":2388,"PHASE4":2390,"NA":2392},{"trials":2383,"activeCount":98},[],{"trials":2385,"activeCount":98},[],{"trials":2387,"activeCount":98},[],{"trials":2389,"activeCount":98},[],{"trials":2391,"activeCount":98},[],{"trials":2393,"activeCount":98},[2394],{"nctId":2256,"briefTitle":2257,"status":727,"phases":2395,"completion":2259,"start":2260,"enrollment":2261,"conditions":2396,"interventions":2397},[90],[18,2263],[2241,2265,2266,2267,2268,2269,2270,2271],{"intervention":2019,"totalTrials":94,"cells":2399},{"EARLY_PHASE1":2400,"PHASE1":2402,"PHASE2":2404,"PHASE3":2406,"PHASE4":2408,"NA":2410},{"trials":2401,"activeCount":98},[],{"trials":2403,"activeCount":98},[],{"trials":2405,"activeCount":98},[],{"trials":2407,"activeCount":98},[],{"trials":2409,"activeCount":98},[],{"trials":2411,"activeCount":98},[2412],{"nctId":2011,"briefTitle":2012,"status":2013,"phases":2413,"primaryCompletion":1933,"completion":2015,"start":1627,"enrollment":699,"conditions":2414,"interventions":2415},[90],[2017],[2019,2020,2021,2022,2023,2024],{"intervention":2021,"totalTrials":94,"cells":2417},{"EARLY_PHASE1":2418,"PHASE1":2420,"PHASE2":2422,"PHASE3":2424,"PHASE4":2426,"NA":2428},{"trials":2419,"activeCount":98},[],{"trials":2421,"activeCount":98},[],{"trials":2423,"activeCount":98},[],{"trials":2425,"activeCount":98},[],{"trials":2427,"activeCount":98},[],{"trials":2429,"activeCount":98},[2430],{"nctId":2011,"briefTitle":2012,"status":2013,"phases":2431,"primaryCompletion":1933,"completion":2015,"start":1627,"enrollment":699,"conditions":2432,"interventions":2433},[90],[2017],[2019,2020,2021,2022,2023,2024],{"intervention":2022,"totalTrials":94,"cells":2435},{"EARLY_PHASE1":2436,"PHASE1":2438,"PHASE2":2440,"PHASE3":2442,"PHASE4":2444,"NA":2446},{"trials":2437,"activeCount":98},[],{"trials":2439,"activeCount":98},[],{"trials":2441,"activeCount":98},[],{"trials":2443,"activeCount":98},[],{"trials":2445,"activeCount":98},[],{"trials":2447,"activeCount":98},[2448],{"nctId":2011,"briefTitle":2012,"status":2013,"phases":2449,"primaryCompletion":1933,"completion":2015,"start":1627,"enrollment":699,"conditions":2450,"interventions":2451},[90],[2017],[2019,2020,2021,2022,2023,2024],{"intervention":2023,"totalTrials":94,"cells":2453},{"EARLY_PHASE1":2454,"PHASE1":2456,"PHASE2":2458,"PHASE3":2460,"PHASE4":2462,"NA":2464},{"trials":2455,"activeCount":98},[],{"trials":2457,"activeCount":98},[],{"trials":2459,"activeCount":98},[],{"trials":2461,"activeCount":98},[],{"trials":2463,"activeCount":98},[],{"trials":2465,"activeCount":98},[2466],{"nctId":2011,"briefTitle":2012,"status":2013,"phases":2467,"primaryCompletion":1933,"completion":2015,"start":1627,"enrollment":699,"conditions":2468,"interventions":2469},[90],[2017],[2019,2020,2021,2022,2023,2024],{"intervention":2024,"totalTrials":94,"cells":2471},{"EARLY_PHASE1":2472,"PHASE1":2474,"PHASE2":2476,"PHASE3":2478,"PHASE4":2480,"NA":2482},{"trials":2473,"activeCount":98},[],{"trials":2475,"activeCount":98},[],{"trials":2477,"activeCount":98},[],{"trials":2479,"activeCount":98},[],{"trials":2481,"activeCount":98},[],{"trials":2483,"activeCount":98},[2484],{"nctId":2011,"briefTitle":2012,"status":2013,"phases":2485,"primaryCompletion":1933,"completion":2015,"start":1627,"enrollment":699,"conditions":2486,"interventions":2487},[90],[2017],[2019,2020,2021,2022,2023,2024],{"intervention":2489,"totalTrials":94,"cells":2490},"Lidocaine",{"EARLY_PHASE1":2491,"PHASE1":2493,"PHASE2":2495,"PHASE3":2497,"PHASE4":2499,"NA":2501},{"trials":2492,"activeCount":98},[],{"trials":2494,"activeCount":98},[],{"trials":2496,"activeCount":98},[],{"trials":2498,"activeCount":98},[],{"trials":2500,"activeCount":98},[],{"trials":2502,"activeCount":98},[2503],{"nctId":2504,"briefTitle":2505,"status":727,"phases":2506,"primaryCompletion":2507,"completion":2508,"start":2509,"enrollment":2510,"conditions":2511,"interventions":2513},"NCT01780324","Lidocaine Analgesia for Urethral Catheterization in Children",[90],"2014-05","2015-05","2013-01",80,[2512],"Pediatric Presentation of Urinary Tract Infection",[2489]]